The ANP32E Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited pool of human colorectal adenocarcinoma cells in which the ANP32E gene has been disrupted, leading to reduced or absent full-length protein expression. This polyclonal knockout population ensures that phenotypic readouts average out clonal variation, providing a reliable loss-of-function system for mechanistic studies.
The HT29 cell line is a widely used human colorectal adenocarcinoma model with epithelial morphology. Derived from a primary colorectal tumor, HT29 cells exhibit apical?Cbasal polarity, express intestinal markers, and form tight junctions, recapitulating features of absorptive epithelium. This line is a standard platform for studying colorectal cancer biology, intestinal barrier function, and cytotoxic drug response.
ANP32E functions as a histone chaperone specific for H2A.Z, directing its incorporation via the SRCAP chromatin remodeling complex and its eviction by INO80, thereby regulating transcriptional activity and genome stability. In apoptosis regulation, ANP32E binds BCL2 to inhibit cytochrome c release and caspase-3 activation; upon apoptosis induction, caspase-3 cleaves ANP32E, generating fragments that differentially modulate H2A.Z loading and BCL2 interaction. This positions ANP32E at a critical junction between chromatin dynamics and cell survival, with key partners including H2A.Z, BCL2, SRCAP, caspase-3, and cytochrome c.
Knocking out ANP32E in HT29 cells enables investigation of its dual functions in a colorectal cancer background. Aberrant H2A.Z deposition is implicated in oncogenic transcription, and ANP32E??s anti-apoptotic role through BCL2 is highly relevant in tumors where intrinsic apoptosis pathways are often suppressed. This model allows researchers to probe how disrupted nucleosome dynamics and reduced apoptosis inhibition affect tumor cell fitness, chemosensitivity, and metastatic potential.
Key applications include Western blotting and immunofluorescence to verify ANP32E loss and monitor apoptosis markers such as cleaved caspase-3 and cytochrome c; ChIP-qPCR to measure H2A.Z occupancy at target promoters; caspase activity and cell viability/proliferation assays to assess apoptotic and growth responses; and RT-qPCR to profile downstream gene expression changes. These polyclonal knockout cells are also suitable for drug-sensitivity screening with colorectal cancer therapies and can be paired with reconstitution experiments to validate target specificity. For detailed protocols and technical assistance, please contact Ascent Research.
